Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

90.19 +0.43 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
52 53 Next >
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
3 Smart Stocks to Buy if a Recession Is on the Way
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
From Gilead Sciences, Inc.
Via Business Wire
16 Analysts Have This to Say About Gilead Sciences
Via Benzinga
Mount Gilead, NC Author Publishes Children's Book
So Excited, She Runs To Solve The Mystery Of What She Is Smelling. 
Via PR Leap
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
Via Benzinga
This New Drug Could Be Gilead Sciences' Growth Catalyst
Another potential blockbuster drug in Gilead's hands. 
Via The Motley Fool
3 Stocks That Beat the S&P During the Great Recession
These stocks could be safe places to store your money if a recession takes place this year. 
Via The Motley Fool
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing. 
Via Talk Markets
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Global Cell and Gene Therapy Market will worth USD 21,508 million by 2028-end at a CAGR of 28.2% from 2022 to 2028 according to Intelligence Market Report 
Via SBWire
Peering Into Gilead Sciences's Recent Short Interest
Gilead Sciences's (NASDAQ:GILD) short percent of float has fallen 15.71% since its last report. The company recently reported that it has 14.76 million shares sold short, which is 1.18% of all regular... 
Via Benzinga
2 Unstoppable Stocks That Could Beat the Market Again In 2023
Thankfully, it's not too late to buy these stocks. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Via Benzinga
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall. 
Via Investor's Business Daily
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
From Gilead Sciences, Inc.
Via Business Wire
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
Which of these companies is better able to replace declining COVID-19-related sales? 
Via The Motley Fool
FTX Exchange's Assets Worth $3.5B Held By Bahamian Regulators, Italy PM To Meet Intel Over Chip Investment, New Oral COVID Antiviral Might Be Better Than Pfizer's Paxlovid: Today's Top Stories
Reuters 
Via Benzinga
New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
A study in China shows that a remdesivir analog, dubbed VV116, is as effective as Pfizer Inc's (NYSE: PFE) oral COVID-19 pill. 
Via Benzinga
3 High-Yielding Dividend Stocks That Could See Hikes in January
These stocks all pay more than 3% in dividends. 
Via The Motley Fool
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Via Benzinga
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Gilead will try to win approval for what is now GS-1811, while Jounce develops other immunotherapy drugs. JNCE stock is soaring. 
Via InvestorPlace
Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S. markets opened lower on Tuesday in a truncated week after rising bond yields dragged major growth stocks and indices. 
Via Benzinga
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
3 Stocks That Could Soar in a Santa Claus Rally
These stocks are primed for a holiday surge. 
Via The Motley Fool
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
The market uptrend is under pressure. 
Via Investor's Business Daily
3 Nasdaq Stocks That Are Up 25% in 3 Months
Should you jump on the bandwagon and buy these surging stocks? 
Via The Motley Fool
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.